IFNA1 and chronic hepatitis B virus infection: Recent clinical studies have demonstrated that an optimized treatment regimen based on pegylated interferon alpha (Peg-IFN-α) can significantly increase HBsAg loss in selected patients with dominant chronic hepatitis B (Bazinet et al., 2020; Hu et al., 2018; Ning et al., 2014).